Zydus Lifesciences Ltd. on Thursday said it has received final approval from the US health regulator to market its generic version of Dapsone gel used to treat acne.
The final approval by the US Food and Drug Administration is for Dapsone gel of strength 7.5%, Zydus Lifesciences said in a regulatory filing.
Dapsone gel is used to treat acne and will be manufactured at the group's topical manufacturing facility in Changodar, Ahmedabad, it added.
ADVERTISEMENT
Dapsone gel, 7.5% had annual sales of $35.8 million in the US, Zydus Lifesciences said citing IQVIA MAT March 2024 data.
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU
Northern Arc Capital Gets Board Nod To Raise Rs 5,000 Crore Via NCDs
Aug 25, 2025
Modi In Gujarat: Projects Worth Rs 5,400 Crore To Be Launched — Check Details
Aug 25, 2025
Garbage Bag With Girlfriend's Parcel Leads To 'Wake-up Call' For Bengaluru Man
Aug 21, 2025
Nagaland Governor La Ganesan Dies At 80
Aug 16, 2025
POPULAR
1
Vaishno Devi Landslide: Adityanath Announces Rs 4 Lakh Ex Gratia For Victims From UP
2
UP Liquor Exports Set To Cross 1,000 Million Litres By 2026: Industry Body
3
IATA Proposes Higher Age Limit Of 67 Years For Pilots Operating Commercial Flights
4
Delhi Traders See US Tariff Hike As Temporary Setback, Urge Support For Exports
5